Eton Pharmaceuticals

ETON13F as of Jun 30, 2026 · next update ~Nov 14

Limited coverage

Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.

Who's buying ETON

Top funds mostly added to Eton Pharmaceuticals in Q2 (Apr⁠–⁠Jun)

Buying:

Funds1InsidersCongress

Top funds
1 of 1 bought more, 0 sold some. Largest: Polen Capital Management, $1.6M (0% of its portfolio).
Insiders
No buys, 8 sales in 12 months.
Congress
No trades disclosed in the last 12 months.

1 fund$1.6M held0.0% avg. weightQ2: 1 bought / 0 sold

13F reports are a snapshot as of Jun 30, 2026; funds may have traded since. Insiders often sell for personal reasons (taxes, diversification, planned sales).

Share price · market data, not from 13F reports

Q2 2026

Insider trades (Form 4)

Last 2 years · 12 filings

Net buying$30.08M

Date	Insider	Type	Shares	Price	Value
Aug 28, 2026	Paul V Maier Director	Sold	50,000	$59.07	$2.95M
Aug 24, 2026	David Krempa	Sold	25,000	$65.07	$1.63M
Aug 19, 2026	Sean Brynjelsen President & CEO	Sold	100,000	$60.88	$6.09M
Jul 14, 2026	Opaleye Management Inc. 10% Owner	Sold	28,315	$37.54	$1.06M
Jul 2, 2026	Opaleye Management Inc. 10% Owner	Sold	126,685	$37.64	$4.77M
Jun 17, 2026	Jennifer Mckie Adams Director	Sold	50,000	$32.48	$1.62M
May 28, 2026	Sean Brynjelsen President & CEO	Sold	120,000	$31.88	$3.83M
May 22, 2026	David Krempa	Sold	100,000	$32.30	$3.23M
Aug 19, 2025	James R. Gruber CFO	Sold	41,713	$16.15	$674K
Jun 12, 2025	David Krempa	Sold	34,000	$14.83	$504K
Jun 10, 2025	Opaleye Management Inc. 10% Owner	Bought	7,930	$15.82	$125K
Jun 3, 2025	Sean Brynjelsen President & CEO & 10% Owner	Sold	210,000	$17.11	$3.59M